TSLA
Tesla
-- 248.710 NVDA
NVIDIA
-- 117.700 PLTR
Palantir
-- 90.960 MSTR
Strategy
-- 304.000 SOFI
SoFi Technologies
-- 12.870 
NEWS
Pluri Collaborates with Bar-Ilan University to Advance Cancer Immunotherapy for Solid Tumors, Supported by Israel Innovation Authority
Pluri Inc. (PLUR) announces a collaboration with Bar-Ilan University's BIRAD, funded by the Israel Innovation Authority, to advance cancer immunotherapy using Placental Mucosal Associated Invariant T (MAIT) cells for solid tumors. The partnership combines Pluri's proprietary MAIT cell expansion platform with Prof. Cyrille Cohen's Siglec-based Chimeric Switch Receptors technology to enhance CAR-MAIT's efficacy and tumor specificity. The project aims to develop innovative allogeneic cell therapies targeting solid tumors, addressing a significant unmet medical need. Pluri's MAIT cells, derived from human placentas, offer unique advantages including potency, multiple tumor-targeting mechanisms, and reduced risk of Graft versus Host Disease.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment